Blood Disorders & Hematology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

This phase 3 trial is testing a new combination of pevonedistat and azacitidine for patients with acute myeloid leukemia who cannot undergo standard chemotherapy. This study focuses on older adults or those who are unfit for aggressive treatment. If successful, it may offer a new treatment that is more effective or easier to tolerate, providing hope for better outcomes in a group with limited options.

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

This phase 2 trial is evaluating fitusiran as a preventive treatment for boys aged 1 to under 12 with severe hemophilia A or B. The goal is to reduce bleeding episodes with a simpler treatment approach that may be less burdensome than current options. Although the study is not recruiting now, it is active in several countries including the US and Canada, working to improve quality of life for children with hemophilia.

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

This phase 1 trial tests a new cellular immunotherapy that uses patients’ own T cells, engineered to target B cell non-Hodgkin lymphoma cells. It is designed for patients whose lymphoma has come back or not responded to previous treatments. Conducted at a single US site, this study offers a promising approach to target cancer more precisely and may provide new options for difficult-to-treat cases.

Loncastuximab and Roflumilast Added to R-CHOP for Naïve High-Risk Diffuse Large B-cell Lymphoma

This phase 1 trial is exploring a combination of loncastuximab and roflumilast added to the standard R-CHOP chemotherapy for adults newly diagnosed with high-risk diffuse large B-cell lymphoma. The trial aims to improve response rates and survival in this aggressive form of lymphoma. Recruiting in the US, this study could lead to a new treatment strategy for patients facing this serious diagnosis.

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

This trial is testing 4SCAR19, a gene-modified T cell therapy, for patients with B cell cancers that have returned or not responded to prior treatments. The study is recruiting in China and plans to enroll 200 patients. This therapy aims to provide a new option by harnessing the immune system to fight cancer cells more effectively.

Blood disorder research continues to advance with innovative therapies focusing on improving treatment options for patients with leukemia, lymphoma, hemophilia, and other blood cancers. The trials this week highlight a range of approaches including new drug combinations, gene therapies, and immune-based treatments. These efforts are particularly important for patients who have limited options or cannot tolerate standard therapies. As these studies progress, they may lead to safer and more effective treatments that improve quality of life and outcomes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.